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Abstract: 
Background and aim: Hirschsprung (HSCR) disease is caused by the failure of 
enteric neural crest cells (ENCCs) to fully colonize the bowel, thus leading to bowel 
obstruction and megacolon. Heterozygous mutations in the coding region of the RET 
gene account for the severe form of HSCR (total colonic aganglionosis, TCA). 
However, 80% of HSCR patients have short segment HSCR (S-HSCR), whose 
genetic etiology remains unclear. Here, we aimed to establish a new strategy for the 
functional identification of novel mutation(s) in HSCR disease. Methods: Three 
HSCR-iPSC lines (from 1 TCA-HSCR patient with a RET G731del mutation and 2 S-
HSCR patients without a RET mutation) and two RET isogenic mutant iPSC lines 
(RET+/- and RET-/-) were established to generate disease-relevant ENCCs. The 
migration and differentiation capacities of the iPSC-derived ENCCs were analyzed 
with various in vitro differentiation and migration assays. Disease-associated 
mutation(s) were identified by combining genetic and transcriptomic data obtained 
from patient blood and iPSC-derived ENCCs, respectively. Mutations in HSCR-
iPSCs were corrected with CRISPR/Cas9. Results: ENCCs derived from all diseased 
iPSC lines exhibited defects in migration and neuronal lineage differentiation. RET 
mutations were functionally associated with cellular phenotypes of ENCCs in vitro. 
Integration of genetic and transcriptomic data further identified a novel mutation in 
Vinculin (VCL M209L) associated with S-HSCR. Correcting the RET G731del and 
VCL M209L mutations in HSCR-iPSCs restored the ENCC functions. Conclusion: 
We identified VCL as a novel HSCR gene. Importantly, our results also illustrate the 
value of human iPSCs for defining mutations that functionally contribute to a 
complex disease. Key words: PSC-based model, RET, Vinculin  
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Introduction: 
 
Hirschsprung (HSCR) disease, the most common neurocristopathy, affects ~1 
to 1.3 in 5,000 newborns. It is a complex congenital disorder of the colon, in which 
certain nerve cells are absent, owing to incomplete colonization of the bowel by 
enteric neural crest cells (ENCCs), thus causing functional intestinal obstruction. 
Phenotypic severity is classified according to the length of the aganglionic segment, 
referred to as short segment (S-HSCR: 80% of the patients), long segment (L-HSCR: 
15% of the patients) and total colonic aganglionosis (TCA: 5% of the patients)1. 
HSCR disease is caused by disruptions in the developmental pathways by which 
ENCCs colonize the developing gut and give rise to various subtypes of neurons and 
glia to form a functional enteric nervous system (ENS).   
 
The receptor tyrosine kinase RET and glial cell-derived neurotrophic factor 
(GDNF) constitute the important signaling pathway in ENS development2-4. GDNF 
(from the gut mesenchyme) binds to the RET receptor (expressed in ENCCs) and 
activates effector signaling molecules, which in turn mediate proliferation, migration 
and differentiation of enteric ENCCs. Mutations in the GDNF gene are very rare, 
whereas RET variants/mutations are associated with most HSCR cases. Heterozygous 
mutations in coding (CD) sequences of the RET gene account for only 5-20% of all 
HSCR cases and are primarily associated with TCA, whereas non-coding (NCD) 
variants/single nucleotide polymorphisms spanning the RET gene are frequently 
detected in S-HSCR cases. Both CD and NCD variants/mutations may lead to 
aberrant RET expression. In particular, most of the CD mutations found in the 
extracellular domain of RET disrupt the protein maturation of RET, thus leading to 
decreased RET expression5 and suggesting that haploinsufficiency of RET may 
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represent a cause of HSCR. Ret-/- mutant mice exhibit complete intestinal 
aganglionosis, owing to a combination of cell death and failure to migrate, 
accompanied by kidney defects. Intriguingly, whereas most of the RET CD mutations 
found in patients are heterozygous, heterozygous deletion or mutations of Ret in mice 
are not sufficient to cause an HSCR-like phenotype2-4. Only when Ret expression is 
decreased to approximately one-third of its normal levels do Ret hypomorphic mice 
recapitulate the ENS phenotypes of HSCR patients, including colonic aganglionosis 
with incomplete penetrance, a tendency for males to be affected more frequently than 
females and an absence of kidney defects6. These data suggest that decreased RET 
expression is the underlying cause of HSCR. The biological implications of the NCD 
variants of RET, however, are less defined. The risk allele “T” at rs2435357 in the 
intronic enhancer of the RET gene is the strongest risk allele associated with S-HSCR. 
This genetic variant has been shown to decrease RET expression in a reporter assay7. 
Nevertheless, this risk allele “T” is frequently found in healthy individuals, thus 
suggesting that interplay between and/or accumulation of additional CD or NCD 
functional variants are likely involved in S-HSCR pathogenesis. 
 
In this study, we firstly made use of three induced pluripotent stem cell (HSCR-
iPSC) lines carrying RET CD mutation, a control iPSC line (IMR90) and a “RET-
corrected” HSCR-iPSC line to perform a proof-of-concept study and to establish a 
causal relationship between the genetic mutation with cellular phenotypes “in the 
dish”. We then generated additional HSCR-iPSC lines from two S-HSCR patients 
without RET CD mutation to further demonstrate how a human iPSC model can be 
used to generate disease-relevant cells for the identification of new susceptibility 
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genes as well as for a better understanding of disease etiology (Figure 1 and 
Supplementary Table 1).  
 
Materials and Methods: 
Human iPS cells 
A control human iPS cell line (IMR90-iPSC) was obtained from WiCell Research 
Institute (WiCell, WI). Patient-iPS cell lines were generated from fibroblasts of 
HSCR patients by episomal reprogramming vectors or retroviruses carrying the four 
reprogramming factors and were maintained on Matrigel-coated plates in mTeSR1 
medium. The study was approved by the institutional review board of the University 
of Hong Kong together with the Hospital Authority (UW 13-419). 
 
Plasmid construction 
The human codon-optimized Cas9 expression plasmid was obtained from Addgene 
(44720). Two guide RNA (gRNA) plasmids were prepared using Gibson assembly, 
and the corresponding sequences are listed in Supplementary Table 2. The donor 
plasmid containing the VCL gene spanning the region chr10:74072141-74078191, a 
2229-bp neomycin selection cassette (loxP-neo-Tk) flanked by two loxP sites and an 
HSV-TK promoter was prepared. VCL expression constructs carrying the wild-type 
or HSCR-associated mutation were prepared.  
 
Generation of RET mutant iPS cell lines 
The CRISPR/Cas9D10A system8 was used to target exon 10 or 12 of the RET locus in 
IMR90 human iPS cells. IMR90 iPS cells were transfected with gRNA constructs. 
The colonies were isolated and subjected to screening using PCR and Sanger 
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sequencing. The clones with bi-allelic nonsense mutations were expanded for follow-
up assays. 
 
Correction of the VCL mutation in HSCR-iPS cells 
HSCR-iPSC#3 cells were transfected with the VCL-specific gRNA constructs, a 
Cas9-D10A nickase expression plasmid and a donor plasmid containing the wild-type 
VCL by using Nucleofector. The transfected cells were then plated on Matrigel-coated 
plate, and selection was initiated 24 h later with culture medium containing 100 ng/ml 
neomycin. Neomycin-resistant colonies were obtained in 2-3 weeks and isolated for 
screening. 
 
Neural crest induction 
Human PSCs were plated on Matrigel-coated plates (105 cells cm−2) in ES cell 
medium containing 10 ng/ml FGF2 (PeproTech, 100-18B). Differentiation was 
initiated by replacing the ES medium with KSR medium and then gradually switching 
to N2 medium as described previously 9. For vagal NCC induction, the cells were 
treated with LDN193189, SB431542, CHIR99021, and 1 µM retinoic acid. The 
differentiated cells were sorted for p75NTR and HNK1 or CD49d expression at day 10 
as described 9-12. CNS precursor control cells were generated by treatment with 
LDN193189 and SB431542 from day 0 to day 10 as previously described13.  
 
FACS and flow cytometry analysis 
For flow cytometry analysis or cell sorting, the cells were dissociated with Accutase 
and labeled with anti-human antibodies. The labeled cells were detected using a 
FACSCalibur instrument. Isotype-matched antibodies were used as controls. FlowJo 
 8 
version 8.2 (Tree Star, Inc.) was used to analyze the flow data. A list of primary 
antibodies and working dilutions is provided in Supplementary Table 3.  
 
In vitro differentiation of ENCCs to enteric neurons 
ENCCs (3x104) from the 10-day induction protocol were seeded as droplets on poly-
ornithine/laminin/fibronectin (PO/LM/FN)-coated dishes in N2 medium containing 10 
ng/ml FGF2 and 3µM CHIR99021. Neuronal differentiation was initiated by 
replacing the N2 medium with neuronal differentiation medium containing GDNF, 
ascorbic acid, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), 
neurotrophin-3 (NT-3) and cyclic adenosine monophosphate (cAMP). The ENCCs  
differentiated into neurons in 1–2 weeks. The cells were then fixed for 
immunostaining. 
 
In vitro differentiation of NCCs to mesenchymal lineages 
To drive NCCs toward differentiation into the mesenchymal lineage, purified NCCs 
were incubated in aMEM containing 10% FBS for 2 weeks in uncoated tissue 
culture-grade dishes. hiPS cell–derived neural crest-mesenchymal precursor cells 
(hiPS cell–derived NCMP cells) were identified on the basis of the expression of 
CD73 and were expandable in aMEM containing 10% FBS. hiPS cell–derived 
NCMP cells were then subjected to mesenchymal lineage differentiation by culturing 
in Medium 231 containing a smooth muscle differentiation supplement or in 
Adipogenesis medium, Osteogenesis medium or Chondrogenesis medium for 2-4 
weeks, according to the manufacturer’s protocols. 
 
Cell culture and transfection 
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The VCL expression construct was then transfected into HeLa cells using FuGene® 
HD Transfection Reagent. Cells overexpressing the wild-type or mutated GFP-VCL 
expression constructs were used for subsequent immunofluorescence and 
immunoprecipitation assays.  
 
Immunofluorescence analysis 
For immunofluorescence analysis, the cells were fixed, blocked and then incubated 
with a primary antibody listed in Supplementary Table 3. The cells were 
photographed using a Carl Zeiss confocal microscope (LSM 780). The quantitative 
image analysis of differentiated neuronal cultures was performed using ImageJ 
plugins. The percentage of neuronal cells was measured relative to the total number of 
cells (DAPI), and the values reported in bar charts represent the mean ± SEM.  
 
Migration 
In vitro migratory behaviors of ENCCs were measured using scratch assays. 
 
Immunoblotting & immunoprecipitation 
Total protein (20 µg) from cell lysates was separated on 8% SDS-polyacrylamide gels 
and blotted with specific antibodies listed in Supplementary Table 3. β-Actin 
expression was used as a protein-loading control.  
To study the interaction of VCL and ACTIN, protein lysates were first 
immunoprecipitated with an anti-VCL antibody (Abcam, ab290) and protein A-
agarose beads. The immunoprecipitates were separated by SDS-polyacrylamide gels 
and blotted with antibodies against ACTIN or VCL. All blots were incubated with a 
horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody. 
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RNA and exome sequencing 
RNA and exome sequencing were performed in the Centre of Genomic Science, The 
University of Hong Kong. The differential expression (DE) analyses were performed 
using DESeq2. The significance level was set at 0.05 for false discovery rate (FDR)-
corrected p-values.   
 
Network and functional enrichment analyses 
A gene association network analysis was performed by GeneMANIA14. The resulting 
network bridged the genotyping and expression data. DAVID was used to detect 
enrichment of any particular similar type of genes15.  
 
Protein structure prediction 
 SWISS-MODEL16 was used to predict the structure of the mutated VCL 
protein.  
 
Experimental details are available in the supplementary methods. 
 
Results: 
Establishment of diseased and disease-corrected HSCR-iPSC lines 
Because RET/GDNF signaling is crucial for ENCC development and RET 
mutations account for most cases of HSCR, here, we introduced a homozygous or 
heterozygous RET CD mutation in a control iPSC to test whether the HSCR-
associated phenotypes and the disease severity can be captured in an iPSC-based 
model.  We used the CRISPR/Cas9 system to specifically target the transmembrane or 
intracellular tyrosine kinase domain of RET and generated two isogenic iPSC lines 
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with compromised or reduced RET/GDNF signaling (Figure 2A). The heterozygous 
(IMR90RET+/-) clone carries a 19 bp insertion in one allele that leads to a premature 
termination of the RET protein (RET+/E734Kfs*#40=>) and is equivalent to a heterozygous 
deletion of RET (IMR90RET+/-) (Figure 2B). Another isogenic iPSC line carries two 
independent mutations in the two alleles of the RET gene, which cause a truncation 
deletion (allele 1: R606X) and a 2-amino acid deletion (allele 2: 601-602del) in the 
RET protein (Figure 2C).  
 
An important aim of this study was to examine whether patient-specific iPSCs 
can be used to study the effects of genetic lesions and to model disease development. 
Many of the RET CD mutations interrupt ENCC development, thereby contributing to 
the severe form of HSCR (TCA). Therefore, a TCA-HSCR patient with a 
heterozygous CD mutation in exon 12 of the RET gene (G731del), which led to a 
single amino-acid deletion, was included in this study (Figure 2D). Skin fibroblasts 
were obtained from this patient and were reprogrammed into iPSCs with episomal 
vectors17 (referred to as HSCR#6-iPSCs, Supplementary Figure 1). The presence of 
the RET G731del mutation in both the fibroblasts and iPSCs was confirmed by 
Sanger sequencing. 
 
To determine how these mutations affect RET protein expression, we 
transfected plasmids carrying the wild-type or mutant RET cDNA into a human 
epithelial cell line (HeLa). A western blot analysis revealed that the E734Kfs*#40=> 
mutation in exon 12 of the RET gene causes premature termination leading to 
decreased total RET expression level in the IMR90RET+/- line (Figure 2E, Ex12). In the 
IMR90RET-/- line, the R606X (Ex10 A1) truncation mutation in allele 1 (A1) led to 
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premature termination of the RET protein, whereas the 601-602del mutation in the 
second allele (Ex10 A2) decreased the RET level. Therefore, we speculated that 
RET/GDNF signaling in the IMR90RET-/- line would be largely compromised. 
Therefore, comparing these two isogenic clones with their parental control line would 
allow us to establish a causal link between impaired RET/GDNF signaling and ENCC 
defects and, in turn, define the disease-relevant phenotypes in the dish. 
 
To directly address the biological effect of this mutation, a genetically 
matched control line was established by correcting this RET mutation in HSCR#6-
iPSCs by using the CRISPR/Cas9 genome-editing platform with a specific pair of 
gRNAs and a donor plasmid carrying the wild-type (WT) RET, as shown in Figure 
2F. The corrected clone (HSCR#6-RET corrected-iPSC) had the same genetic 
background as HSCR#6-iPSCs but carried a WT RET gene, and the correction was 
confirmed by Sanger sequencing (Figure 2G). These two iPSC lines were used for 
subsequent functional analyses to directly address how RET G731del might interfere 
with human ENCC development. 
  
S-HSCR is the most common form of HSCR, and many affected individuals 
do not carry any CD mutation in RET or in other known HSCR genes. Therefore, to 
generate iPSC lines, as described above, skin fibroblasts were obtained from two 
individual S-HSCR patients who did not carry any RET CD mutations (referred to as 
HSCR#3 and HSCR#5) (Supplementary Figures 2 & 3).  
 
Derivation of ENCCs from diseased iPSC lines 
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To recapitulate the progressive differentiation process that occurs during 
normal ENCC development, we used a stepwise differentiation protocol10. Human 
iPSCs were first differentiated into multipotent NCCs before being further 
differentiated into neurons, including neurons expressing pan-neuronal or ENS-
specific neuronal markers (Figure 3A). Cranial and vagal NCCs were derived from 
control and diseased iPSCs through previously described protocols in the absence and 
presence of retinoic acid (RA), respectively9-11, 13, 18 (Figure 3B). To prospectively 
identify and isolate NCCs from the heterogeneous population, cell sorting was 
performed on day 10 with antibodies against HNK-1 and p75NTR (Figure 3B). 
Comparison of the transcription profiles of HNK-1 and p75NTR double-positive 
cranial and vagal NCCs derived from the control iPSC line (IMR90) showed that 
almost 3000 genes were commonly expressed in these two populations and that 
approximately 1,000 genes were uniquely expressed in each population. Additional 
comparisons made for the expression of NCC marker genes (TWIST1, TFAP2A, 
SOX10, PAX3, NGFR, FOXD3 and EDNRB) showed that all these genes were 
expressed in HNK-1+p75NTR+ populations. In particular, HNK-1+p75NTR+ NCCs 
derived in the presence of RA showed high expression levels of these genes, which 
were accompanied by high levels of HOXB family genes (HOXB2-5, but not 
HOXB9). This gene expression pattern was consistent with that of enteric NCCs 
(Figure 3C). Most of the HNK-1+p75NTR+ NCCs also co-expressed CD49d, RET 
(Figure 3D) and SOX10 (Figure 3E). As early as day 9 in neuronal differentiation 
medium, the expression levels of various pan-neuronal markers (TUJ1, PGP9.5, and 
HU), PHOX2B and markers for enteric neuron subtypes such as TH (dopaminergic 
neuron), VIP (inhibitory neuron) and ChAT (excitatory neuron) were detectable 
(Figure 3F). These neuronal cells formed more mature neurons with extended 
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neuronal processes and became responsive to electric stimulation after they were 
cultured in vitro for another week (day 16) (Supplementary Figure 4). Both the gene 
expression patterns and cellular phenotypes of HNK-1+p75NTR+ NCCs were consistent 
with those of mouse and human pluripotent stem cell-derived enteric NCCs, as 
defined in a recent paper by Fattahi et. al.10. Hereafter, the HNK-1+p75NTR+ NCCs 
derived in the presence of RA will be termed “ENCCs”. All diseased iPSC lines 
(IMR90RET-/-, IMR90RET+/-, HSCR#3, HSCR#5 and HSCR#6) and the control line 
(IMR90) generated ENCCs at comparable yields (Figure 3G).  
 
HSCR-associated phenotypes were recapitulated in the dish with iPSCs 
RET expression in ENCCs derived from the diseased iPSC lines carrying RET 
CD mutations were analyzed using flow cytometry with an antibody against the 
intracellular domain of RET. The percentages of RET+ cells obtained from the two 
isogenic iPSC lines (IMR90RET-/- and IMR90RET+/-) were consistently decreased by 
~40-50%, as compared with their parental line (IMR90). A similar observation was 
found in the HSCR#6-iPSC line, but significantly more RET-expressing ENCCs were 
obtained when the mutation was corrected (RET Corrected) (Figure 4A). We then 
examined how RET mutations interfere with the responsiveness of ENCCs to GDNF, 
on the basis of their neuronal differentiation capability, as monitored by the 
expression of a pan-neuronal marker (TUJ1). In the presence of GDNF, robust 
neuronal differentiation was observed in ENCCs carrying WT RET. IMR90RET+/- 
ENCCs differentiated into neurons less efficiently, whereas this process was almost 
completely abolished when both copies of the RET gene were interrupted in 
IMR90RET-/- ENCCs (Figure 4B). As demonstrated in scratch assay, retarded 
migration was also observed in these two RET mutant lines, as predicted 
 15 
(Supplementary Figure 4). Similar defects were found in HSCR#6 ENCCs. Diseased 
ENCCs exhibited severe differentiation defects with very weak TUJ1 expression and 
extremely short neuronal fibers. Retarded migration of these cells was observed in the 
scratch assays, and the addition of GDNF did not promote their migration. 
Importantly, both the differentiation capacity (Figure 4C) and migratory behavior 
(Figure 4D) of ENCCs derived from HSCR#6-iPSCs was restored when the RET 
mutation was corrected. This proof-of-concept study indicated that HSCR-associated 
disease phenotypes and severity can be recapitulated in the dish using human iPSCs. 
 
Similarly to the RET mutant ENCCs, ENCCs derived from the two S-HSCR 
iPSC lines (HSCR#3 and HSCR#5) also exhibited neuronal differentiation and 
migration defects, as monitored by in vitro differentiation and scratch assays (Figure 
4E-F). The diseased ENCCs exhibited defects in the formation of axon outgrowth and 
various subtypes of neurons. The expression of pan-neuronal markers (e.g., TUJ1, 
PGP9.5) was dramatically decreased in diseased ENCCs. The percentages of RET 
expressing cells derived from these two S-HSCR-iPSC lines were only slightly lower 
than that of the healthy controls (IMR90-iPSC and RET-corrected HSCR#6-iPSC) 
(Supplementary Figure 6). Notably, the migration and differentiation defects in S-
HSCR-ENCCs were relatively less severe than those of cells carrying RET CD 
mutations. 
 
Disease-associated differentiation defects are lineage specific 
The greatest concern regarding the analyses of S-HSCR iPSC lines is the 
differences in the genetic background among individuals, and comparisons were 
usually made between patients and an unmatched control. The different cellular 
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phenotypes observed in the control and patient cells may have been due to the 
significant biological heterogeneity of iPSC lines derived from different individuals. 
Therefore, we used a more rigorous approach to assess the differentiation defects of 
the control and S-HSCR-iPSC lines. First, CNS progenitors were generated from the 
control and diseased iPSC lines in a condition favoring the induction of CNS 
progenitors, in which the same neural induction medium was used, but cells were 
seeded at a higher cell density, as previously described11 (Figure 5A). A comparable 
amount of CNS progenitors (PAX6+) was obtained from the control and S-HSCR-
iPSC lines (Figure 5B). Intriguingly, CNS progenitors from both the control and 
diseased cells efficiently differentiated further and generated various subtypes of 
neurons, as monitored by the expression of pan-neuronal markers (TUJ1, HU, 
PGP9.5) and subtype-specific neuronal markers (e.g., VIP, TH and nNOS) (Figure 
5C).   
 
We then tested the differentiation plasticity of the diseased NCCs toward non-
neuronal NC lineages, such as adipogenic, osteogenic and chondrogenic lineages. 
Cranial NCCs were first generated in the absence of RA treatment through the same 
differentiation protocol as described above. FACS-sorted cranial NCCs derived from 
the control and diseased iPSCs were directed to a mesenchymal lineage, thus forming 
hiPSC–derived neural crest-mesenchymal precursor cells (hiPSC–derived NCMP 
cells). These hiPSC–derived NCMP cells were subsequently used to generate 
adipocytes, osteocytes or chondrocytes (Figure 5D). Comparable amounts of cranial 
NCCs were obtained from the control (IMR90) and S-HSCR-iPSC (HSCR#3 & 
HSCR#5) lines (Figure 5E), and 75-88% of these cells co-expressed SOX10 (Figure 
5F). In addition, there were no obvious differences between the control and diseased 
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cells in their capacities to generate NCMP cells (Figure 5G) and their derivatives, 
such as adipocytes (Figure 5H), osteocytes (Figure 5I) and chondrocytes (Figure 5J). 
Therefore, the neuronal differentiation defects observed in the S-HSCR-iPSCs were 
restricted to the NC lineage, whereas the CNS lineage was not affected.   
 
Identification of disease-associated pathways and mutations for S-HSCR  
To gain mechanistic insights into the disease-related mechanisms underlying 
S-HSCR, the transcriptomes of the fibroblast cells, iPSCs and their NC derivatives 
(ENCCs) from the patient and control groups were obtained through RNA 
sequencing. A principal component analysis (PCA) of these profiles showed a good 
separation between the different types of cells. Control and patient fibroblast cells and 
iPSCs showed similar expression signatures and clustered together, whereas their 
ENCC derivatives exhibited more distinctive gene expression profiles 
(Supplementary Figure 7). A subsequent gene ontology (GO) analysis of the control 
and S-HSCR-iPSC-derived ENCCs showed a significant enrichment of GO terms 
associated with cell junction assembly/migration and neuronal differentiation (Figure 
6A). 
 
 It is challenging to identify causative mutations for a rare and complex 
disease. Therefore, we established a new strategy to identify novel functional 
mutation(s) in S-HSCR by using our established iPSC platform, with a particular 
focus on HSCR#3. We used a two-tiered approach to define how genetic variation(s) 
functionally contribute to disease phenotypes (Figure 6B). We first identified 
candidate genes by comparing the transcriptomes of the control and the diseased cells. 
Gene differentially expressed at the different developmental stages (iPSC versus NC 
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derivatives) of a given cell line (longitudinal expression study) were first identified 
and were then used for the cross sectional comparison between the patient and the 
control groups (Supplementary methods). 735 genes were DE in the longitudinal 
study of the control derived cell line and 562 from the patient-derived cell line.  When 
patient and control DE genes were compared, 299 genes were differentially expressed 
in the patient cells but not in the control cells during ENCC differentiation 
(Supplementary Table 4), thus suggesting that these changes may alter the 
differentiation path in the patient (Supplementary methods).  Noteworthy, when we 
used a pool of 20 other iPSC lines (from our data and a public database) as controls, a 
total of 179 genes were found to be differentially expressed in HSCR#3-iPSC. This 
result might indicate that HSCR#3-iPSCs carry some genetic alterations that also lead 
to dysregulation at the very first step of differentiation. After shortlisting the potential 
candidate genes, to further narrow down the list of potentially causative gene(s), we 
then combined the transcriptome data with the whole-exome sequencing data 
obtained from sequencing the blood DNA sample of the patient. From the whole-
exome sequencing study of this patient, we identified genetic variations in 267 genes 
predicted to be damaging (sftp://odds.cgs.hku.hk). These genes were appended to the 
network analysis of the differentially expressed according to our cross sectional 
analyses. GeneMANIA identified genes (network nodes) present in the association 
networks created from the cross sectional genes (Figure 6C). Among those genes, 
VCL was notable. This gene is a nexus among multiple differentially expressed genes 
in the networks. In addition, according to the GO enrichment of the networked genes, 
VCL interacts with multiple genes involved in “axon guidance”.  
 
Functional dissection of the Vinculin M209L in HSCR pathogenesis 
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VCL is an essential protein required for focal adhesion (FA) assembly through 
binding to its partner proteins, including talin19, actin20 and paxillin21. Mutations 
interrupting FA assembly or affecting the size and position of FAs may interfere 
various cellular processes such as cellular movement or differentiation. In our patient, 
VCL contained a M209L substitution in the head domain of the protein. SWISS-
MODEL modeling suggested that the M209L substitution might alter the 
conformation of the loop structure in the folded protein (Figure 7A). To determine 
whether VCL M209L affects the FAs dynamics and contributes to disease phenotypes, 
we corrected the VCL mutation in HSCR#3-iPSCs by using a CRISPR/Cas9-mediated 
targeting approach (Figure 7B and Supplementary Figure 8).  To this end, FA 
assembly was examined in the diseased and disease corrected ENCCs based on the 
expression pattern of VCL and its interacting partners (Phalloidin (actin) and Paxillin).  
In addition, the mean size of FA (FA size) in ENCCs was measured based on the 
expression of Paxillin (a FA marker).  Consistently, we found that the FA size of 
ENCCs derived from HSCR#3-iPSCs significantly smaller than that of the control 
(IMR90) ENCCs. Correction completely rescued this defect (Figure 7C). This 
phenomenon was recapitulated by overexpression of a VCL M209L mutant in HeLa 
cells, thus suggesting that the decreased FA size was the result of a mutation in VCL 
that led to the M209L substitution (Figure 7D). A subsequent immunoprecipitation 
(IP) assay further revealed that the M209L substitution decreased VCL-actin binding 
(Figure 7E). Intriguingly, correction of the VCL mutation alone in HSCR#3-iPSCs 
efficiently restored the differentiation (Figure 7F) and migration (Figure 7G) 
capacities of ENCCs. In particular, neurons derived from corrected ENCCs possessed 
extended axons, which were highly similar to those of the wild-type cells (Figure 7F). 
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Discussion: 
 In this study, we demonstrated how human pluripotent stem cells (hPSCs) can 
be used to model HSCR disease phenotypes and to correlate the genetic lesions and 
disease severity in the dish. More importantly, we also identified a new experimental 
approach by combining the genetic data obtained directly from patient blood DNA 
and the transcription profile of the disease-relevant cells, to identify mutation(s) 
functionally contributing to disease phenotypes for a complex disease.  
 A recent meta-analysis comparing the transcriptional patterns of various hPSC 
lines has revealed that transcriptional differences between genetically unrelated hPSC 
lines are primarily driven by genetic background rather than cellular origin or 
reprogramming method22, and these differences may affect cellular behaviors. 
Therefore, we performed a comprehensive study on eight healthy and diseased iPSC 
lines and used various approaches to illustrate how iPSCs can be used to model 
HSCR disease. First, we defined the disease phenotypes in the culture dish with iPSC 
lines carrying CD mutations in RET, the best-characterized HSCR gene. These two 
RET isogenic mutant lines (IMR90RET+/- and IMR90RET-/-) showed comparable RET 
levels, but RET/GDNF signaling was partially or totally compromised. Comparisons 
between these two isogenic mutant lines and their parental line lined the dosage effect 
of RET/GDNF signaling with cellular phenotypes, thus reflecting disease severity. 
More importantly, we also showed that ENCC functions were restored by correction 
of a single RET CD mutation (RET G731del) in a patient-specific iPSC line (HSCR#6) 
derived from a TCA-HSCR patient. This finding further suggested that patient-
specific iPSCs are a reliable system for mechanistic studies of the genetic etiology 
underlying HSCR disease. In particular, HSCR-associated genetic lesions probably 
 21 
affect the early events of NCC development, which can be monitored on the basis of 
the differentiation and migration capacities of iPSC-derived ENCCs in vitro.    
 The genetic etiology of S-HSCR probably involves rare or common variants, 
acting alone or in combination; thus, a disease model carrying the same genetic 
background of the patient would have advantages for functionally interconnecting 
mutation(s) with disease phenotypes. We generated patient-specific iPSCs from 2 S-
HSCR patients carrying the most common RET NCD variant. These S-HSCR-iPSC 
lines allowed us to assess the combined effects of all HSCR-relevant variants present 
in a given patient. First, we linked the cellular phenotypes in the dish with the disease 
phenotypes of the patients. CNS progenitors and cranial NCCs were derived from the 
control and S-HSCR iPSCs by using three highly comparable differentiation protocols 
differing only in cell densities and RA treatment. The differentiation capacities 
toward CNS neurons and non-neuronal NC lineages were examined. Our data clearly 
indicated that the differentiation defects were restricted to certain lineages and 
recapitulated the patient phenotypes. We further pinpointed the disease-relevant 
mutations by integrating the genetic data obtained from the whole-exome sequencing 
of patient blood DNA and the expression profiles of ENCCs derived from patient 
iPSCs. Combining these two datasets successfully increased the statistical power and 
allowed us to identify the disease-relevant mutation(s). As shown by our analysis, the 
whole-exome sequencing data identified more than two hundred mutations from the 
patient genomic DNA. After integrating the transcriptional data obtained from iPSC-
derived ENCCs, a single VCL (M209L) mutation was found to be the most relevant.  
 VCL has been implicated in several developmental processes, including 
cardiac myocyte and NCC development23, 24. Vcl null mutants die at embryonic day 
10, owing to failure of rostral neural tubule closure. The cranial and spinal nerve 
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development are also compromised25. In our functional study, we demonstrated that 
the VCL M209L substitution led to decreased FA size in the patient ENCCs, and such 
changes may directly interfere with the cellular behavior of ENCCs and their 
responses to the environment, thereby causing defects in differentiation and migration. 
Consistently with these results, a gene ontology analysis also suggested that migration 
and axon guidance pathways are affected in these diseased cells. More importantly, a 
subsequent rescue experiment clearly demonstrated that the VCL M209L substitution 
functionally contributes to the disease phenotypes. 
 An advantage of our experimental approach was its high power for 
identification of the most relevant genetic changes from the disease-relevant cells. In 
addition, integrating the genetic data obtained directly from patient blood DNA with 
the transcriptomic data of the disease-relevant cells further eliminated the effect of 
systemic inherent variability due to different genetic background or mutations 
artificially introduced during the culturing process. The use of highly comparable 
differentiation protocols to test the differentiation plasticity of the control and 
diseased cells toward various lineages also minimized the error associated with in 
vitro differentiation systems. Importantly, the experimental paradigm established here 
is generally applicable for mechanistic studies of various complex diseases.  
 
 In summary, we identified a novel mutation in VCL that is a possible 
contributor to HSCR. In addition, we also established a new strategy by combining 
patient-specific iPSCs, the CRISPR/Cas9 system and whole-exome sequencing data 
to identify mutations functionally contributing to a complex disease. 
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Figure legends: 
Figure 1. Generation of disease-relevant cells for studying genetic lesions 
associated with HSCR disease. (A) Schematic for the generation of diseased and 
healthy ENCCs from iPSCs. Diseased iPSC (HSCR-iPSC) lines were generated by 
reprogramming the patient fibroblast cells or by introducing a disease-associated 
mutation into the control iPSCs through a genome-editing approach. The genetically 
matched control iPSC lines were the disease-corrected iPSC and the parental cells of 
the mutant lines. ENCCs were derived from the diseased and healthy iPSC lines. The 
cellular behavior and expression profiles of the diseased ENCCs were compared with 
their genetically matched controls. The table summarizes the key experiments 
performed in this study. (B) Overview of healthy and diseased fibroblasts, iPSC lines 
and their derivatives used for functional analyses and RNA-seq. 
 
Figure 2. Generation of diseased iPSC lines. (A) Generation of isogenic iPSC lines 
carrying homozygous or heterozygous RET mutations. (B) IMR90RET+/- line: a 
heterozygous mutation was introduced into exon 12 of the RET gene. (C) IMR90RET-/- 
carries a truncation deletion and a 2 amino-acid deletion mutation in allele 1 (A1) and 
allele 2 (A2), respectively. The DNA and amino acid sequences of the two isogenic 
RET mutant iPSC lines (IMR90RET+/- and IMR90RET-/-) are shown. (D) DNA and 
amino acid sequences of the RET gene in an iPSC (HSCR#6) line derived from a 
TCA-HSCR patient carrying the RET G731del mutation in exon 12, affecting the 
tyrosine kinase domain of RET. (E) Western blot analysis of protein lysates obtained 
from HeLa cells overexpressing wild-type (WT) or mutant RET. The red arrow 
indicates the full-length RET. (F) Targeting strategy for correcting the RET G731del 
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mutation in the HSCR#6-iPSC line. (G) Correction of the RET G731del mutation was 
confirmed by Sanger sequencing.  
 
Figure 3. Derivation of ENCCs from iPSC lines. (A) Schematic of the generation of 
ENCCs and their derivatives. (B) Stepwise differentiation protocol for the generation 
of vagal and cranial NCs in the presence or absence of retinoic acid (RA), 
respectively. (C) Transcriptional profiles of vagal and cranial HNK-1+/p75NTR+ NCCs 
were obtained by RNA sequencing. The Venn diagram shows differentially expressed 
genes (DEGs) between vagal and cranial NCCs. The expression levels of various 
NCC markers and HOX genes in these two NCC populations are shown in the bar 
charts. (D) Flow cytometry analysis of the co-expression of CD49d and RET in the 
HNK-1+/p75NTR+ NCCs. (E) Immunocytochemistry was used to monitor the 
expression of SOX10. (F) In vitro differentiation assays indicated the differentiation 
plasticity of ENCCs, as monitored by the expression levels of markers of various 
neuronal subtypes. TUJ1: beta-tubulin; PGP9.5: protein gene product 9.5; HU: HU 
neuronal protein; PHOX2B: paired-type homeobox protein; TH: tyrosine 
hydroxylase; VIP: vasoactive-intestinal polypeptide; ChAT: choline acetyltransferase. 
(G) Flow cytometry analyses to quantify HNK-1+/p75NTR+ ENCCs derived from 
control and diseased iPSC lines. The mean values from 6 independent assays are 
shown.  
 
Figure 4. RET-deficient ENCCs exhibit defects in migration and differentiation. 
(A) Flow cytometry analyses were used to measure RET-expressing ENCCs derived 
from control (IMR90), two isogenic RET mutant (IMR90RET+/- and IMR90RET+/-), 
HSCR#6 and RET-corrected HSCR#6 iPSC lines. The percentages of RET+ ENCCs 
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are shown in the bar chart (mean ± SEM from 4-6 independent experiments). (B & C) 
The neuronal differentiation of control and disease ENCCs after GDNF treatment 
(100 µg/ml) was monitored on the basis of the expression of TUJ1. Scale bars = 50 
µm. Quantitative data are shown in the bar chart. (D) Scratch assays were performed 
to measure the migratory ability of iPSC-derived ENCCs. The bar charts show wound 
closure measured as the percentage of scar width over time (18 h). (E) In vitro 
differentiation analysis of ENCCs derived from two S-HSCR (HSCR#3 and 
HSCR#5) iPSC lines. Their differentiation plasticity was measured on the basis of the 
expression of the pan-neuronal markers TUJ1, PGP9.5 (protein gene product 9.5), and 
HU and the ENS-related neuronal markers VIP (vasoactive intestine peptide) and 
ChAT (choline acetyltransferase). Quantitative data are shown in the bar charts. (F) 
Scratch assays on ENCCs derived from control and S-HSCR iPSCs. The bar chart 
shows wound closure, measured as the percentage of scar width over time (18 h). The 
data shown in the bar charts are from at least three independent assays.  
 
 
Figure 5. Differentiation defects of patient cells are lineage specific. (A) 
Schematic of the derivation of CNS progenitors and derivatives. (B) Comparable 
CNS progenitors (PAX6+) were obtained from control and diseased iPSC lines. (C) 
CNS progenitors derived from control and diseased iPSCs showed similar capacities 
to form various subtypes of neurons. (n=3) (D) Cranial NCCs were generated from 
control and diseased iPSC lines and subsequently differentiated into non-neuronal NC 
lineages. (E) All S-HSCR-iPSC lines showed comparable capacities to form cranial 
NCCs and co-expressed SOX10. (F) A comparable amount of NCMPs was obtained 
from control and diseased lines. The NCMPs did not show obvious differences in 
generating adipocytes, osteocytes and chondrocytes.  
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Figure 6. RNA sequencing data identify disease-associated pathways. (A) GO 
analyses of genes differentially expressed in S-HSCR ENCCs. (B) Schematic of the 
integrated analysis of RNAseq data and whole-exome sequencing data obtained from 
HSCR-iPSC-derived ENCCs and patient blood DNA, respectively. The degree of 
overlap of the RNA and exome sequencing indicates a causal gene/pathway and 
disease relationship. (C) GeneMANIA shows genes (network nodes) present in the 
association networks created from the longitudinal and cross sectional analyses by 
combining the genetic and transcription data from HSCR#3.  
 
 
Figure 7. VCL M209L mutation causes delayed migration and defective 
formation of neuronal axons. (A) Schematic showing that the M209L substitution 
resides in the head domain of VCL in proximity to the talin binding region. SWISS-
MODEL indicates that the M209L substitution alters the protein conformation of 
VCL. (B) Sanger sequencing confirmed that the HSCR#3-iPSCs and corrected cells 
are carrying mutant and wild-type VCL, respectively. (C) Immunocytochemistry 
analysis of VCL, Phalloidin, and Paxillin in control, HSCR#3 and VCL-corrected 
HSCR#3-iPSC derived ENCCs. Upper panel: The co-localization of VCL with 
Phalloidin at the focal adhesion (FA) is highlighted and magnified as shown in the 
insets. Lower panel: FAs were identified based on the expression of Paxillin and the 
areas marked with a dashed line were measured using ImageJ and considered as the 
FA size. The bar chart shows the average FA size in control, HSCR#3, and VCL-
corrected ENCCs. (D) Immunocytochemistry analysis of phalloidin and paxillin in 
HeLa cells overexpressing wild-type or mutant VCL. Upper panel shows the 
colocalization of VCL with Phalloidin at the FAs. Lower panel indicates that the size 
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of FA marked by Paxillin was smaller in the mutant VCL-overexpressing HeLa cells. 
The bar chart shows the average FA size in the wild-type or mutant VCL-
overexpressing HeLa cells. (E) Western blot (WB) analysis confirmed comparable 
expression levels of wild-type or mutant VCL in transfected cells. Co-
immunoprecipitation (co-IP) indicated decreased actin binding of mutant VCL. (F) 
An in vitro differentiation assay revealed that correction of the VCL mutation restores 
the differentiation capacity of ENCCs. Corrected cells possess more axon outgrowth, 
marked by arrowheads. The percentages of cells expressing various neuronal markers 
derived from HSCR#3 and corrected iPSCs are shown in the bar chart. (G) Scratch 
assays on HSCR#3 and VCL-corrected iPSC-derived ENCCs. The bar chart shows 
wound closure measured as the percentage of scar width over time (18 h). The data 
shown in the bar charts are from at least three independent assays.  
 
 
 
 















hiPSC lines Gender Phenotype 
RET 
Rs2435357 
(C/T) 
 Known mutation  
IMR90 F WT C/C   - 
IMR90RET+/- F - C/C  RET E734Kfs*#40 =>/+ 
IMR90RET-/- F - C/C  RET G606X/G601-602del 
HSCR#6 F TCA C/C  RET G731del/+ 
HSCR#3 M S-HSCR VSD/ASD T/T  VCL M209L 
HSCR#5 M S-HSCR T/T  N.D. 
HSCR#3 VCL 
Corrected M - T/T  VCL WT 
HSCR#6 RET 
Corrected F - C/C  RET WT 
 
Supplementary Table 1: List of human induced pluripotent stem cell (hiPSC) lines 
used in this study. F: female; M: male; WT: wild-type; S-HSCR: short HSCR; TCA: 
total colonic aganglionsis; VSD/ASD: ventricular septal defect/atrial septal defect; 
N.D.: not determined.  
Supplementary Table 2: List of oligos used in this study 
Target gene Oligo sequence Annealing 
Temp (°C) 
Product 
Size (bp) 
Experiment used 
RET Exon 10 gRNA #1: 5’-CATAGCCAGCTTTAATCCCCCGGG-3’ 
gRNA #2: 5’-ACCTGCAACTGCTTCCCTGAGGT-3’ 
- - Gene targeting 
RET Exon 12 gRNA #1: 5’-CAAGAACCAAGTTCTTCCGAGGG-3’ 
gRNA #2: 5’- CGAATTTGGAAAACTCCTCAAGG-3’ 
- - Gene targeting 
VCL Exon 6 gRNA #1: 5’-CAAGAACCAAGTTCTTCCGTGGG-3’ 
gRNA #2: 5’-CGAATTTGGAAAAGTGGTCAAGGC-3’ 
- - Gene targeting 
RET Exon 10 Forward: 5’- AGGCTGAGTGGGCTACGTCT-3’ 
Reverse: 5’- TGCTGTTGAGACCTCTGTGG-3’ 
58 208 PCR sequencing 
RET Exon 12 Forward: 5’- AGCCATTCACAGTCCAGGTC-3’ 
Reverse: 5’- CACGTAAGCAATACGGGTCA-3’ 
58 285 PCR sequencing 
VCL Exon 6 Forward: 5’- AAAGCCCAAAACATCTAAAGTG-3’ 
Reverse: 5’- GGGGATTTTGCTTATTTCTCC-3’ 
58 295 PCR 
sequencing 
VCL Forward: 5’- CAGTCAGACCCTTACTCAGTGC-3’ 
Reverse: 5’- GCTAAAGCGCATGCTCCAGAC-3’ 
58 1588 PCR 
VCL Forward: 5’-GTTGTTACAAAAATCTTCAAAGCTGAAATGAGAACTGGCAGC-3’ 
Reverse: 5’- GCTGCCAGTTCTCATTTCAGCTTTGAAGATTTTTGTAACAAC-3’ 
58 - Mutagenesis 
sihVCL sRNA#1: 5’-GGAAGAAAUCACAGAAUCAUU-3’ 
sRNA#2: 5’-CCAGAUGAGUAAAGGAGUAUU-3’ 
- - knockdown 
VCL Exon 12 gRNA #1 5’-GAAAGATCAGAAAGTAAGCT-3 
gRNA #2 5’-ACTAAAAACTCAAAAAACCAAGG- 3’  
   
RET Forward: 5’-ACACCAAGGCCCTGCGGCG-3’ 
Reverse: 5’-GGAAGGTCATCTCAGCTGAG-3’ 
56 681 PCR 
HOXB3 Forward: 5’- CCAGTGCCACTAGCAACAGC -3’ 
Reverse: 5’- CGTTTGCCTCGACTCTTTCATC -3’ 
60 128 PCR 
HOXB4 Forward: 5’- GACCATTACCTCGACACCCG -3’ 
Reverse: 5’- AACACTGCACTATCTGGCAGTCAG -3’ 
60 157 PCR 
HOXB5 Forward: 5’- AAACTCCTTCTCGGGGCGTTAT -3’ 
Reverse: 5’- CATCCCATTGTAATTGTAGCCGT -3’ 
60 139 PCR 
SOX10 Forward: 5’- ACTTCGGCAACGTGGACATT -3’ 
Reverse: 5’- CAGCCACATCAAAGGTCTCCAT -3’ 
72 60 PCR 
SNAIL2 Forward: 5’- ATGAGGAATCTGGCTGCTGT -3’ 
Reverse: 5’- CAGGAGAAAATGCCTTTGGA -3’ 
60 119 PCR 
ACTIN Forward: 5’- ACTCTTCCAGCCTTCCTTCC -3’ 
Reverse: 5’- CGTCATACTCCTGCTTGCTG -3’ 
60 291 PCR 	
Supplementary Table 3: List of antibodies used in this study 
Target Protein Description Company 
Cat no. 
Working 
conc 
Experiment 
used 
RET  APC-conjugated anti-human RET Neuromics FC15017 - 
Flow 
cytometry 
RET Goat anti-RET Neuromics GT15002 1:1000 WB 
HNK-1 APC-conjugated anti-human CD57 (HNK1) BD Pharmingen 560845 - 
FACS/flow 
cytometry 
p75NTR FITC-conjugated anti-human CD271 (p75NTR) Miltenyi Biotec 130-091-917 - 
FACS/flow 
cytometry 
Integrin α  FITC-conjugated anti-human CD49d Biolegend 304414  
FACS/flow 
cytometry 
SOX2 Goat anti-SOX2 R&D system MAB2018 1:500 IF 
SOX10 Mouse anti-SOX10 R & D system MAB2864 1:500 
IF 
OCT-4 Goat anti-OCT-4 Santa Cruz SC-5279 1:100 
IF 
NANOG Goat anti-NANOG R&D system AF1997 1:500 
IF 
SSEA-4 Mouse anti-SSEA-4 R&D system FAB1435P 1:200 
IF 
TRA-1-60 Mouse anti-TRA-1-60 Millipore MAB4360 1:100 
IF 
HNK1 Mouse monoclonal anti-HNK1 Sigma C6680 1:200 
IF 
p75NTR Rabbit anti- p75NTR Abcam Ab8874 1:500 
IF 
TUJ1 Mouse monoclonal anti-TUJ1 Convance PRB-435P                  1:500 
IF 
HU Mouse monoclonal anti-HU Invitrogen A21275 1:500 
IF 
TH Rabbit anti-TH Novus NB300-109 1:200 
IF 
VIP Rabbit anti-VIP Millipore AB1581 1:200 
IF 
PGP9.5 Rabbit anti-PGP9.5 Abcam ab10404 1:100 
IF 
ChAT Rabbit anti-ChAT Millipore AB143 1:200 
IF 
nNOS Rabbit anti-nNOS Cell Signalling 4231 1:200 
IF 
Neurofilament Mouse anti-Neurofilament Sigma N5139 1:200 
IF 
PHOX2B Goat anti-PHOX2B Santa Cruz Sc-13224 1:100 
IF 
GFAP Rabbit anti-GFAP DAKO Z0334 1:200 
IF 
S100B Rabbit anti-S100B Sigma S2644 1:500 
IF 
PAX6 Rabbit anti-PAX6 DSHB 1:200 IF 
SM22α Rabbit polyclonal anti-SM22 alpha Abcam  Ab14106 1:500 IF 
CALPONIN Rabbit monoclonal anti Calponin Abcam Ab46794 1:100 IF 
PAXILLIN  Mouse monoclonal anti Paxillin line 5H11 Millipore 05-417 1:2000 IF 
PHALLOIDIN Alexa Flour 594 Phalloidin ThemoFisher 1:100 IF 
A12381 
VINCULIN Mouse monoclonal anti-Vincullin Sigma A4731 1:2000 IF/IP 
GFP Rabbit polyclonal anti-GFP Abcam AB290 1:300 IP 
ACTIN Mouse monoclonal anti-actin Millipore MAB1501 1:10000 WB 
Mouse IgG1 κ  APC-conjugated mouse IgG1 κ isotype control 
BD Pharmingen 
554681 - 
FACS/flow 
cytometry 
Mouse IgG/IgM FITC-conjugated goat anti-mouse IgG/IgM BD Pharmingen 555988 - 
FACS/flow 
cytometry 
Mouse IgM APC-conjugated rat anti-mouse IgM BD Pharmingen 550676 - 
FACS/flow 
cytometry 
Mouse IgG HRP conjugated anti-mouse antibody DAKO 1:2500 WB 
Rabbit IgG HRP conjugated anti-rabbit antibody DAKO 1:2500 WB 
 
 	
